by Rod Raynovich | Sep 23, 2010 | BIOgraph
Within the “diagnostics and tools” track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in...
by Rod Raynovich | May 11, 2010 | RAG
Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor samples. The BRAF gene encodes a protein involved in cell signaling and...
by Rod Raynovich | May 10, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...
by Rod Raynovich | Apr 20, 2010 | RAG
Yesterday we presented an overview of the use of Biomarkers(BM’s) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer Research(AACR) meeting on Monday.Researchers from Fox Chase Cancer...
by Rod Raynovich | Apr 19, 2010 | BIOgraph
At yesterday’s AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM’s) to predict tumor response and thus...
by Rod Raynovich | Jan 15, 2009 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Monday briefing: Rod Raynovich Webcast at: https://events.jpmorgan.com Biotech Valuations at trough levels About 4000 attendees consisting of mutual and hedge fund investors,VC’s, Company executives and their PR legions registered the...
